BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25466700)

  • 1. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.
    Taylor-Cousar JL; Wiley C; Felton LA; St Clair C; Jones M; Curran-Everett D; Poch K; Nichols DP; Solomon GM; Saavedra MT; Accurso FJ; Nick JA
    J Cyst Fibros; 2015 Mar; 14(2):228-36. PubMed ID: 25466700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
    Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
    J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
    Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
    Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
    Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
    Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of oral sildenafil in cystic fibrosis children with mild to moderate lung disease.
    Reisi M; Modaresi MR; Aghaii Z; Mirlohi SH; Rafiemanesh H; Azizi G; Sayedi SJ
    Pediatr Pulmonol; 2020 Jan; 55(1):156-160. PubMed ID: 31571429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
    Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
    J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Tolerability of Intravenous Sildenafil in Two Subjects with Child-Turcotte-Pugh Class C Cirrhosis and Renal Dysfunction.
    Mindikoglu AL; Dowling TC; Schaub DJ; Hutson WR; Potosky DR; Christenson RH; Barth RN; LaMattina JC; Hanish SI; Weir MR; Raufman JP
    Dig Dis Sci; 2015 Nov; 60(11):3491-4. PubMed ID: 26143343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polysulfated Hyaluronan GlycoMira-1111 Inhibits Elastase and Improves Rheology in Cystic Fibrosis Sputum.
    Kummarapurugu AB; Zheng S; Pulsipher A; Savage JR; Ma J; Rubin BK; Kennedy TP; Voynow JA
    Am J Respir Cell Mol Biol; 2021 Feb; 64(2):260-267. PubMed ID: 33264072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sildenafil improves vascular endothelial function in patients with cystic fibrosis.
    Rodriguez-Miguelez P; Lee N; Tucker MA; Csányi G; McKie KT; Forseen C; Harris RA
    Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1486-H1494. PubMed ID: 30168731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.
    Karandashova S; Kummarapurugu A; Zheng S; Kang L; Sun S; Rubin BK; Voynow JA
    Pediatr Pulmonol; 2018 Jul; 53(7):872-880. PubMed ID: 29624923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.
    Barth P; Bruijnzeel P; Wach A; Sellier Kessler O; Hooftman L; Zimmermann J; Naue N; Huber B; Heimbeck I; Kappeler D; Timmer W; Chevalier E
    J Cyst Fibros; 2020 Mar; 19(2):299-304. PubMed ID: 31501052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.
    Laguna TA; Wagner BD; Luckey HK; Mann SA; Sagel SD; Regelmann W; Accurso FJ
    Chest; 2009 Dec; 136(6):1561-1568. PubMed ID: 19567495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement effectors, C5a and C3a, in cystic fibrosis lung fluid correlate with disease severity.
    Hair PS; Sass LA; Vazifedan T; Shah TA; Krishna NK; Cunnion KM
    PLoS One; 2017; 12(3):e0173257. PubMed ID: 28278205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
    Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
    Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the Process of Discovering Leads That Target the Heparin-Binding Site of Neutrophil Elastase in the Sputum of Cystic Fibrosis Patients.
    Morla S; Sankaranarayanan NV; Afosah DK; Kumar M; Kummarapurugu AB; Voynow JA; Desai UR
    J Med Chem; 2019 Jun; 62(11):5501-5511. PubMed ID: 31074986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between pulmonary function and sputum biomarkers in cystic fibrosis.
    Mayer-Hamblett N; Aitken ML; Accurso FJ; Kronmal RA; Konstan MW; Burns JL; Sagel SD; Ramsey BW
    Am J Respir Crit Care Med; 2007 Apr; 175(8):822-8. PubMed ID: 17234902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis.
    Sagel SD; Wagner BD; Anthony MM; Emmett P; Zemanick ET
    Am J Respir Crit Care Med; 2012 Nov; 186(9):857-65. PubMed ID: 22904182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio
    Ring A; Morris T; Wozniak M; Sullo N; Dott W; Verheyden V; Kumar T; Brunskill N; Vaja R; Murphy GJ
    Br J Clin Pharmacol; 2017 Apr; 83(4):709-720. PubMed ID: 27779776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
    Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
    Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis.
    Konstan MW; Döring G; Heltshe SL; Lands LC; Hilliard KA; Koker P; Bhattacharya S; Staab A; Hamilton A;
    J Cyst Fibros; 2014 Mar; 13(2):148-55. PubMed ID: 24440167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.